help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pipeleers, D.
Right arrow Articles by Somers, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pipeleers, D.
Right arrow Articles by Somers, G.

Journal of Clinical Endocrinology & Metabolism, Vol 56, 1236-1242, Copyright © 1983 by Endocrine Society

ARTICLES

Five cases of somatostatinoma: clinical heterogeneity and diagnostic usefulness of basal and tolbutamide-induced hypersomatostatinemia

D Pipeleers, E Couturier, W Gepts, J Reynders and G Somers

Five cases of somatostatinoma are reported, four being primarily located in the pancreas and one in the duodenum. The diagnosis was based upon the histological and immunochemical characteristics of tumoral and metastatic tissue. A marked clinical heterogeneity was noted: one patient presented with gallstones, steatorrhea, and diabetes, two patients suffered from severe hypoglycemic attacks, and two cases were admitted for obstructive jaundice. This varying symptomatology was related to differences in the circulating levels of biologically active somatostatin and to a variable cellular composition of the tumor. In all cases, a basal and/or tolbutamide-induced hypersomatostatinemia was measured. It is concluded that the clinical and hormonal features of the earlier defined somatostatinoma syndrome are no requisite for the diagnosis of somatostatinoma; the analysis of plasma somatostatin immunoreactivity might lead to a higher detection rate of this endocrine tumor.


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
N. Garbrecht, M. Anlauf, A. Schmitt, T. Henopp, B. Sipos, A. Raffel, C. F Eisenberger, W. T Knoefel, M. Pavel, C. Fottner, et al.
Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity
Endocr. Relat. Cancer, March 1, 2008; 15(1): 229 - 241.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
S Angeletti, V D Corleto, O Schillaci, M Marignani, B Annibale, A Moretti, G Silecchia, F Scopinaro, N Basso, C Bordi, et al.
Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours
Gut, June 1, 1998; 42(6): 792 - 794.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1983 by The Endocrine Society